Scorr-Insert
X

Find Immunology Drugs in Phase II Clinical Development in SWEDEN

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KAND567

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 20, 2020

            Details:

            Kancera plans a Phase II trial of its fractalkine receptor inhibitor KAND567 to prevent hyperinflammation in COVID-19 patients before they develop acute respiratory distress syndrome.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABY-035

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Inmagene Biopharmaceuticals

            Deal Size: $225.5 million Upfront Cash: $10.0 million

            Deal Type: Partnership May 15, 2020

            Details:

            The parties will develop and commercialize ABY-035 for multiple auto-immune diseases. Inmagene will Commercialize ABY-035 in mainland China, Hong Kong, Taiwan, and Macau, and South Korea, and will run developmental activities in the Asia Pacific region.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rabeximod

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 29, 2020

            Details:

            This proactive and strategic decision follows the initiation of preparatory work for substance capsulation that started early this year and is part of the Phase IIb program.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Imlifidase

            Therapeutic Area: Immunology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2020

            Details:

            The completion of enrollment in the anti-GBM study marks an important milestone for the Company's expansion outside transplantation.